Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LGD-6972
- Development stage
- Discontinued
- Lead developer
- Ligand Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LGD-6972 is a novel, orally bioavailable small molecule glucagon receptor antagonist (GRA) developed for the treatment of type 2 diabetes mellitus. It acts by selectively and competitively binding to the glucagon receptor (GCGR), thereby inhibiting its activity and reducing hepatic glucose production. This mechanism targets hyperglycemia in type 2 diabetes by lowering both fasting and postprandial plasma glucose levels through a non-insulin-dependent pathway. Clinical studies have shown that LGD-6972 produces robust, dose-dependent reductions in hemoglobin A1c (HbA1c) with a favorable safety profile compared to other GRAs[1][3][4][5][6]. The drug is structurally distinct from other GRAs due to its sulphonic acid tail, which may contribute to its unique pharmacological properties[6]. Developed as an adjunct to diet and exercise, it has demonstrated efficacy in patients inadequately controlled on metformin monotherapy[5].
- Brand names
- RVT-1502RVT1502RVT 1502
- Other names
- LGD-6972LGD6972LGD 6972
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on LGD-6972.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LGD-6972.